Radiopharm Theranostics Ltd - RADX
Detailed investor-level table based on 13F positions.
Methodology:
Market value and % of portfolio use SEC reported VALUE ($000).
For PUT/CALL positions this reflects reported underlying exposure, not premium cash paid/received.
Details.
Rows: 0
| Investor | History | Status | Shares held | Market value ($000) | % of portfolio | Previous % | Rank | Change in shares | % change in shares | Source | Date reported |
|---|---|---|---|---|---|---|---|---|---|---|---|
| HSBC HOLDINGS PLC | History | New | 191,624 | 1,006 | 0.0% | — | 1 | +191,624 | New | Q4 2025 | Mar 06, 2026 |
| SILVERARC CAPITAL MANAGEMENT, LLC | History | No change | 187,406 | 978 | 0.14% | 0.14% | 2 | 0 | 0.0% | Q4 2025 | Feb 12, 2026 |
| Stonepine Capital Management, LLC | History | New | 51,000,000 | 850 | 0.62% | — | 3 | +51,000,000 | New | Q4 2025 | Feb 13, 2026 |
| Regal Partners Ltd | History | No change | 90,909 | 474 | 0.03% | 0.04% | 4 | 0 | 0.0% | Q4 2025 | Feb 18, 2026 |
| PNC FINANCIAL SERVICES GROUP, INC. | History | No change | 16,000 | 83 | 0.0% | 0.0% | 5 | 0 | 0.0% | Q4 2025 | Feb 06, 2026 |
| Virtu Financial LLC | History | New | 14,591 | 76 | 0.0% | — | 6 | +14,591 | New | Q4 2025 | Feb 23, 2026 |
| JANE STREET GROUP, LLC | History | New | 14,469 | 75 | 0.0% | — | 7 | +14,469 | New | Q4 2025 | Feb 12, 2026 |
| UBS Group AG | History | Reduced | 14,277 | 74 | 0.0% | 0.0% | 8 | -3,914 | -21.52% | Q4 2025 | Jan 29, 2026 |
| Marex Group plc | History | New | 10,285 | 53 | 0.0% | — | 9 | +10,285 | New | Q4 2025 | Feb 12, 2026 |
| Strategic Wealth Partners, Ltd. | History | New | 10 | 0 | — | — | — | +10 | New | Q4 2025 | May 12, 2026 |
| RHUMBLINE ADVISERS | History | New | 6 | 0 | — | — | — | +6 | New | Q4 2025 | Feb 13, 2026 |